India, June 12 -- Suven Life Sciences Ltd. has announced that it will present three scientific posters on its lead drug candidate Samelisant (SUVN-G3031) at SLEEP 2026 Annual Meeting, being held in Baltimore from June 14-17, 2026.
Samelisant is being developed for the treatment of Narcolepsy, and the presentations will highlight the drug's clinical progress, including positive Phase 2 efficacy results and the company's global Phase 3 development program, known as the AWAKE Study.
The three poster presentations will cover Phase 2 results demonstrating a significant reduction in excessive daytime sleepiness (EDS) among narcolepsy patients, the design and rationale of a Phase 2 study evaluating Samelisant for the treatment of cataplexy in Ty...